There has never been a time in medical progress when clinical trials in liver disease have been more important than they are right now. Mount Sinai Liver doctors are pioneering the use of many new drugs for hepatitis C, hepatitis B and liver cancer.
There are over 40 new drugs for hepatitis C undergoing testing now in the United States and we are participating in clinical trials at Mount Sinai in many of them. We firmly believe that to provide the best possible clinical care, we must make clinical trials available to our patients. This gives patients the option to enroll in cutting-edge research of new drugs before they are on the market. Mount Sinai offers patients clinical trials with interferon-free medications, which is a new oral treatment without the side effects often associated with interferon drugs.
Clinical trials for preventing liver fibrosis (scarring), measuring fibrosis without liver biopsy with a machine called a Fibroscan, for fatty liver and for primary biliary cirrhosis are all ongoing in various stages at the Division for Liver Diseases.
Mount Sinai laboratory researchers work hand-in-hand with our team of clinical researchers, studying liver disease from lab bench to bedside. Teams of physician-scientists meet daily to develop short and long-term research agendas to keep Mount Sinai on the cutting-edge of medical science. All these factors translate into doing the best research so we can provide superb clinical care to our patients and offer them the best options for treatment for all liver diseases.
Search our clinical trials.
5 East 98th Street, 11th Floor
New York, NY 10029
275 Seventh Avenue, 12th Floor
New York, NY 10001